Table 3.

The Efficacy of Endostar+NACT for Cervical Patients

Efficacy (n1=n2=69)		Endostar Group	NACT Group	Fisher’s Exact Test	P value
Short-term efficacy(%)	Complete response	55(79.7%)	36(52.1%)	α<0.05	0.0002
	Partial response	7(10.1%)	14(20.2%)	α>0.05	0.1539
	Stable	4(5.8%)	3(4.3%)	α>0.05	1.0000
	Response rate	62(89.9%)	50(72.4%)	α<0.05	0.0155
	Disease control	66(95.6%)	53(76.8%)	α<0.05	0.0001
Long-term efficacy(%)	Overall survival	60(87.0%)	49(71.0%)	α<0.05	0.0355
	Progression-free survival	67(97.1%)	58(84.1%)	α<0.05	0.0028
	Local relapse-free	66(95.7%)	59(85.5%)	α<0.05	0.0329
	Metastasis-free survival	64(93.3%)	56(81.4%)	α<0.05	0.0193